Mizuho raises Lam Research stock price target to $380 on WFE outlook

Mizuho raised Lam Research’s price target to $380 from $330 and lifted fiscal 2027/2028 estimates to $31B/$8.31 EPS and $39B/$10.63 EPS, citing stronger AI-driven wafer fab equipment demand. The firm also flagged 2026/2027 WFE forecasts of $153B/$190B, supported by TSMC, Samsung, Micron and Intel spending trends. Offset somewhat by valuation concerns and China shipment restrictions, but the overall analyst tone remains constructive.

Analysis

The setup is broader than one equipment vendor rerating: this is a capital-spending reflexive loop where AI demand is pulling forward both logic-node upgrades and memory capacity additions. That matters because the most likely near-term beneficiaries are not the most obvious AI hardware names, but the levered picks-and-shovels exposed to multi-year node transitions and packaging intensity; the next-order beneficiaries should be consumables, advanced packaging toolmakers, and the small set of suppliers with pricing power on replacement cycles. Lam’s move implies the market is beginning to price a 2026-2028 earnings bridge that was previously discounted as too distant, which usually expands the investable universe beyond the lead stock.

The key risk is not demand evaporation, but digestion risk: when capex expectations get raised this quickly, the first miss tends to come from timing, not end-demand. Any delay in TSMC 2nm ramps, a pause in HBM spending, or export-control friction on China shipments can create air pockets of 10-20% in equipment names even while the long-term thesis stays intact. That argues for expressing the view with defined-risk structures rather than outright chase, because the valuation move has likely front-loaded part of the 2027 story.

The contrarian read is that the market may be underestimating how concentrated the upside has become: if only a handful of foundries and memory vendors are driving the WFE cycle, supplier order books may get more volatile, not less. That means investors should look for relative winners with lower China sensitivity and higher exposure to advanced packaging / process complexity, rather than simply owning the highest-beta equipment name after a large run.

A second-order implication is that the cycle could spill into test, metrology, and service revenue with a lag of 2-4 quarters, offering a cleaner entry point once the initial capex rerating stabilizes. If the AI buildout sustains into 2027, the eventual winners may be the names that monetize installed base growth and service attach rates rather than only headline tool shipments.

Key Decisions for Investors

• Stay long LRCX only via call spreads or a call calendar into the next 2-3 quarters; upside is still intact, but the stock has likely priced part of the 2027 estimate step-up, so defined risk is preferable to cash equity.
• Add TSM as a lower-volatility expression of the same capex cycle over a 6-12 month horizon; it is the cleaner beneficiary of 2nm and packaging intensity, with less single-product execution risk than equipment suppliers.
• Initiate a relative-value pair: long semi capex beneficiaries with lower China exposure / higher service mix, short a basket of China-sensitive equipment suppliers, targeting 8-12% dispersion over the next 1-2 quarters if export restrictions tighten.
• Watch for a pullback in LRCX or peers after the next guidance round and use that weakness to buy 2026 upside via options; a 15-20% drawdown would likely reset risk/reward more favorably than buying at prior highs.
• Keep INTC on the radar as a lagging beneficiary, but treat it as a catalyst-driven trade only if 18A and packaging commitments become concrete; otherwise, the story is too execution-dependent for size.